Cardiovascular risks in patients with ulcerative colitis: the role of assessing the markers of systemic inflammation and metabolic activity of intestinal microbiota

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Studies indicate an increased risk of subclinical atherosclerosis and early cardiovascular events in patients with ulcerative colitis (UC). Increased cardiovascular risk (CVR) in UC patients is difficult to explain by traditional factors due to their limited prevalence. Systemic inflammation and disorder of metabolic activity of intestinal microbiota, in particular, short-chain fatty acids (SCFA) synthesis are considered in terms of the mechanisms underlying association of UC with pathological conditions of cardiovascular system.

The aim: to study the role of systemic inflammation and metabolic activity of intestinal microbiota in the formation of CVR in UC patients.

Material and methods. The indexes of systemic inflammation SIRI, SII, AISI were determined and compared in 184 patients with UC, 17 of whom had coronary heart disease (CHD). Comparison groups included 20 patients with a combination of arterial hypertension and CHD and 20 practically healthy individuals. At the second stage of the study, the content of SCFAs in feces was assessed in 80 patients with UC, and a correlation analysis was performed to clarify the correlation between systemic inflammation and the content of SCFAs. Parametric and nonparametric statistical methods were used.

Results. In healthy individuals, the values of the SIRI, SII and AISI indexes were significantly lower than in other study participants. They were highest in patients with UC, while SII index was significantly higher in patients who had a combination of UC with coronary heart disease and arterial hypertension. In participants with UC, the content of SCFAs in feces was below the reference values. The acetate/propionate/butyrate ratio was 13.9:2.3:1. A negative correlation was fixed between the values of SIRI, SII and AISI with the content of SCFAs.

Conclusion. Probably, SII index can be considered as a laboratory marker for assessing CVR in case of UC, but additional studies are needed to confirm this. We have established an inverse relationship between the level of systemic inflammation and the metabolic activity of the intestinal microbiota in UC patients with a marked decrease in butyrate synthesis.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Galiya Bikbavova

Omsk State Medical University of the Ministry of Healthcare of Russia

Хат алмасуға жауапты Автор.
Email: galiya1976@mail.ru
ORCID iD: 0000-0001-9252-9152
SPIN-код: 6103-6690

MD, PhD (Medicine), associate professor, associate professor of the Department of hospital therapy, endocrinology

Ресей, Omsk

Maria Livzan

Omsk State Medical University of the Ministry of Healthcare of Russia

Email: rector@omsk-osma.ru
SPIN-код: 1961-4082

MD, Dr. Sci. (Medicine), professor, corresponding member of RAS, rector, head of the Department of faculty therapy and gastroenterology

Ресей, Omsk

Natalya Lisyutenko

Omsk State Medical University of the Ministry of Healthcare of Russia

Email: n.labuzina@mail.ru
ORCID iD: 0000-0003-4088-240X
SPIN-код: 1964-5202

MD, PhD (Medicine), associate professor of the Department of hospital therapy and endocrinology

Ресей, Omsk

Viktor Dranitsyn

Omsk State Medical University of the Ministry of Healthcare of Russia

Email: viktordranicyn@list.ru
ORCID iD: 0009-0001-6030-0131

MD, 1st year resident of the Department of oncology, radiation therapy of continuing professional education

Ресей, Omsk

Lyubov Mikhaleva

Regional Clinical Hospital

Email: lyubov5.04@mail.ru
ORCID iD: 0000-0003-0331-1640

MD, physician at the Department of gastroenterology

Ресей, Omsk

Әдебиет тізімі

  1. Gros B, Kaplan GG. Ulcerative colitis in adults: A review. JAMA. 2023;330(10):951–65. PMID: 37698559. https://doi.org/10.1001/jama.2023.15389
  2. Бикбавова Г.Р., Ливзан М.А., Лозинская М.Ю. Факторы патогенеза язвенного колита: мейнстрим-2020. Бюллетень сибирской медицины. 2021;20(2):130–138. [Bikbavova GR, Livzan MA, Lozinskaya MYu. Pathogenesis factors of ulcerative colitis: Mainstream 2020. Byulleten sibirskoy meditsiny = Bulletin of Siberian medicine. 2021;20(2):130–138 (In Russ.)]. EDN: LSOSFI. https://doi.org/10.20538/1682-0363-2021-2-130-138
  3. Gordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M et al. ECCO Guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18(1):1–37. PMID: 37351850. https://doi.org/10.1093/ecco-jcc/jjad108
  4. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. PMID: 34458905. https://doi.org/10.1093/eurheartj/ehab484
  5. Chen B, Collen LV, Mowat C, Isaacs KL, Singh S, Kane SV et al. Inflammatory bowel disease and cardiovascular diseases. Am J Med. 2022;135(12):1453–60. PMID: 36058305. https://doi.org/10.1016/j.amjmed.2022.08.012
  6. Xu H-M, Zhao H-L, Guo G-J, Xu J, Zhou Y-L, Huang H-L, Nie Y-Q. Characterization of short-chain fatty acids in patients with ulcerative colitis: A meta-analysis. BMC Gastroenterol. 2022;22(1):117. PMID: 35272614. PMCID: PMC8908609. https://doi.org/10.1186/s12876-022-02191-3
  7. Andoh A. Physiological role of gut microbiota for maintaining human health. Digestion. 2016;93(3):176–81. PMID: 26859303. https://doi.org/10.1159/000444066
  8. Liu B, Wang J, Li Y-Y, Li K-P, Zhang Q. The association between systemic immune-inflammation index and rheumatoid arthritis: Evidence from NHANES 1999–2018. Arthritis Res Ther. 2023;25(1):34. PMID: 36871051. PMCID: PMC9985219. https://doi.org/10.1186/s13075-023-03018-6
  9. Gonzalez-Sierra M, Quevedo-Rodríguez A, Romo-Cordero A, Gonzalez-Chretien G, Quevedo-Abeledo JC, de Vera-González A et al. Relationship of blood inflammatory composite markers with cardiovascular risk factors and subclinical atherosclerosis in patients with rheumatoid arthritis. Life (Basel). 2023;13(7):1469. PMID: 37511843. PMCID: PMC10381769. https://doi.org/10.3390/life13071469
  10. Zhou Q, Su S, You W, Wang T, Ren T, Zhu L. Systemic inflammation response index as a prognostic marker in cancer patients: A systematic review and meta-analysis of 38 cohorts. Dose Response. 2021;19(4):15593258211064744. PMID: 34987341. PMCID: PMC8689621. https://doi.org/10.1177/15593258211064744
  11. Muhammad S, Fischer I, Naderi S, Jouibari MF, Abdolreza S, Karimialavijeh E et al. Systemic inflammatory index is a novel predictor of intubation requirement and mortality after SARS-CoV-2 infection. Pathogens. 2021;10(1):58. PMID: 33440649. PMCID: PMC7827801. https://doi.org/10.3390/pathogens10010058
  12. Xu Y, He H, Zang Y, Yu Z, Hu H, Cui J et al. Systemic inflammation response index (SIRI) as a novel biomarker in patients with rheumatoid arthritis: A multi-center retrospective study. Clin Rheumatol. 2022;41(7):1989–2000. PMID: 35266094. https://doi.org/10.1007/s10067-022-06122-1
  13. Клинические рекомендации. Язвенный колит. Российская гастроэнтерологическая ассоциация, Ассоциация колопроктологов России. 2017. Доступ: https://www.ruproctology.com/jour/article/view/291?locale=ru_RU (дата обращения – 22.05.2025). [Clinical guidelines. Ulcerative colitis. Russian Gastroenterological Association, Association of Coloproctologists of Russia. 2017. URL: https://www.ruproctology.com/jour/article/view/291?locale=ru_RU (date of access – 22.05.2025) (In Russ.)].
  14. Клинические рекомендации. Артериальная гипертензия у взрослых. Общероссийская общественная организация «Российское кардиологическое общество». Рубрикатор клинических рекомендаций Минздрава России. 2020. ID: 62_2. Доступ: https://cr.minzdrav.gov.ru/preview-cr/62_2 (дата обращения – 22.05.2025). (Clinical guidelines. Arterial hypertension in adults. Russian Society of Cardiology. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2020. ID: 62_2. URL: https://cr.minzdrav.gov.ru/preview-cr/62_2 (date of access – 22.05.2025) (In Russ.)].
  15. Клинические рекомендации. Стабильная ишемическая болезнь сердца. Российское кардиологическое общество. Рубрикатор клинических рекомендаций Минздрава России. 2020. ID: 155_1. Доступ: https://cr.minzdrav.gov.ru/preview-cr/155_1 (дата обращения – 22.05.2025). [Clinical guidelines. Stable coronary artery disease. Russian Society of Cardiology. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2020. ID: 155_1. URL: https://cr.minzdrav.gov.ru/preview-cr/155_1 (date of access – 22.05.2025) (In Russ.)].
  16. Шварц В.А., Ле Т.Г., Энгиноев С.Т., Сокольская М.А., Испирян А.Ю., Шварц Е.Н. с соавт. Ассоциация новых маркеров системного воспаления с риском развития впервые возникшей послеоперационной фибрилляции предсердий при использовании колхицина у пациентов при операциях на открытом сердце. Анналы аритмологии. 2023;20(1):22–33. [Shvartz VA, Le TG, Enginoev ST, Sokolskaya MA, Ispiryan AYu, Shvartz EN et al. Association of new markers of systemic inflammation with the risk of developing postoperative atrial fibrillation for the first time when using colchicine in patients undergoing open-heart surgery. Annaly aritmologii = Annals of Arrhythmology. 2023;20(1):22–33 (In Russ.)]. EDN QIJQBL. https://doi.org/10.15275/annaritmol.2023.1.3
  17. Осипова О.А., Шепель Р.Н., Агарков Н.М., Гостева Е.В., Демко В.В., Кузуб А.А., Брижанева А.С. Факторы, ассоциированные с ухудшением инотропной функции миокарда у пациентов с ишемической болезнью сердца. Кардиоваскулярная терапия и профилактика. 2024;23(8):6–15. [Osipova OA, Shepel RN, Agarkov NM, Gosteva EV, Demko VV, Kuzub AA, Brizhaneva AS. Factors associated with deterioration of inotropic myocardial function in patients with coronary heart disease. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2024;23(8):6–15 (In Russ.)]. EDN: HHJBEI. https://doi.org/10.15829/1728-88002024-4081
  18. Yang P, Xue R, Wei Y, Cao C, Yu S, Peng S et al. Prognostic value of the derived inflammatory marker SIRI in postmenopausal women with coronary artery disease. Front Cardiovasc Med. 2024;11:1418781. PMID: 39759498. PMCID: PMC11695340. https://doi.org/10.3389/fcvm.2024.1418781
  19. Yang Y, Hua Y, Zheng H, Jia R, Ye Z, Su G et al. Biomarkers prediction and immune landscape in ulcerative colitis: Findings based on bioinformatics and machine learning. Comput Biol Med. 2024;168:107778. PMID: 38070204. https://doi.org/10.1016/j.compbiomed.2023.107778
  20. Cesaro N, Valvano M, Monaco S, Stefanelli G, Fabiani S, Vernia F et al. The role of new inflammatory indices in the prediction of endoscopic and histological activity in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol. 2025;37(1):24–32. PMID: 39292974. PMCID: PMC11608588. https://doi.org/10.1097/MEG.0000000000002842
  21. Carrillo-Palau M, Vera-Santana B, Morant-Domínguez A, Hernández-Camba A, Ramos L, Alonso-Abreu I et al. Hematological composite scores in patients with inflammatory bowel disease. J Clin Med. 2023;12(23):7248. PMID: 38068300. PMCID: PMC10706900. https://doi.org/10.3390/jcm12237248
  22. Tamer F, Edek YC, Aksakal AB. Effect of treatment with biologic agents on the novel inflammatory biomarkers systemic immune inflammation index and systemic inflammation response index for psoriasis. Dermatol Pract Concept. 2024;14(1):e2024065. PMID: 38364414. PMCID: PMC10868908. https://doi.org/10.5826/dpc.1401a65
  23. Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63(8):1275–83. PMID: 24021287. https://doi.org/10.1136/gutjnl-2013-304833
  24. Kumari R, Ahuja V, Paul J. Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India. World J Gastroenterol. 2013;19(22):3404–14. PMID: 23801832. PMCID: PMC3683678. https://doi.org/10.3748/wjg.v19.i22.3404
  25. Kaczmarczyk O, Dąbek-Drobny A, Woźniakiewicz M, Paśko P, Dobrowolska-Iwanek J, Woźniakiewicz A et al. Association between fecal levels of short-chain fatty acids and serum pro- and anti-inflammatory cytokines in patients with inflammatory bowel disease. Folia Med Cracov. 2022;62(1):43–55. PMID: 36088592. https://doi.org/10.24425/fmc.2022.141690
  26. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987;28(10):1221–27. PMID: 3678950. PMCID: PMC1433442. https://doi.org/10.1136/gut.28.10.1221
  27. Russo E, Giudici F, Fiorindi C, Ficari F, Scaringi S, Amedei A. Immunomodulating activity and therapeutic effects of short chain fatty acids and tryptophan post-biotics in inflammatory bowel disease. Front Immunol. 2019;10:2754. PMID: 31824517. PMCID: PMC6883404. https://doi.org/10.3389/fimmu.2019.02754
  28. Balmer ML, Ma EH, Bantug GR, Grählert J, Pfister S, Glatter T et al. Memory CD8(+) T cells require increased concentrations of acetate induced by stress for optimal function. Immunity. 2016;44(6):1312–24. PMID: 27212436. https://doi.org/10.1016/j.immuni.2016.03.016
  29. Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S. Short chain fatty acids and its producing organisms: An overlooked therapy forIBD? EBioMedicine. 2021;66:103293. PMID: 33813134. PMCID: PMC8047503. https://doi.org/10.1016/j.ebiom.2021.103293
  30. Facchin S, Vitulo N, Calgaro M, Buda A, Romualdi C, Pohl D et al. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterol Motil. 2020;32(10):e13914. PMID: 32476236. PMCID: PMC7583468. https://doi.org/10.1111/nmo.13914

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2025